Ergomed Plc (ERGO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ergomed Plc (ERGO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8044
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd is a drug development and clinical research services provider. The company provides service portfolio such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and others. It also provides late phase services such as on-site or remote monitoring, product related pharmacovigilance services, safety management and other supportive services. Ergomed offers co-development services in the treatment areas of oncology and neurology, orphan diseases, and others. The company operates in Croatia, Germany, Russia, the US, Serbia, Poland, the UAE and India, among others. Ergomed is headquartered in Guildford, the UK.

Ergomed Plc (ERGO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ergomed Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ergomed Plc, Medical Devices Deals, 2012 to YTD 2018 10
Ergomed Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ergomed Plc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Haemostatix Raises USD0.1 Million in Venture Financing 13
Partnerships 15
Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 15
Ergomed Enters into Co-Development Agreement with Asarina Pharma 16
Ergomed Enters into Co-Development Agreement with Dilaforette 17
Ergomed Clinical Research Enters Into Co-Development Agreement With Ferrer 18
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 19
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 20
Cel-Sci Expands Co-Development Agreement with Ergomed 21
Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 22
Licensing Agreements 23
Ergomed Enters into Licensing Agreement with Boryung Pharma 23
Equity Offering 24
Ergomed Raises USD5.5 Million in Private Placement of Shares 24
Ergomed Raises USD2.2 Million in Private Placement of Shares 25
Ergomed Announces Underwriter’s Exercise of Over-Allotment Option of Private Placement for USD10.4 Million 26
Ergomed Raises USD19 Million in IPO 27
Acquisition 28
Ergomed Acquires PSR Group for USD6.7 Million 28
Ergomed Acquires Dr.Oestreich +Partner and Gesellschaft fur angewandte Statistik + Datenanalyse 29
Ergomed Acquires Haemostatix 30
Ergomed Acquires Sound Opinion 32
Ergomed Plc – Key Competitors 33
Ergomed Plc – Key Employees 34
Ergomed Plc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 37
Financial Announcements 37
Sep 19, 2018: Ergomed announces unaudited interim results for the six months ended 30 June 2018 37
Apr 11, 2018: Ergomed: Unaudited Preliminary Results for the year ended 31 December 2017 40
Sep 18, 2017: Ergomed: Unaudited Interim results for the six months ended 30 June 2017 41
Mar 28, 2017: Ergomed: Unaudited Preliminary Results for the year ended 31 December 2016 42
Jan 17, 2017: Ergomed to report very strong 2016 revenue growth and order backlog; Poised for significant clinical milestones in 2017 43
Corporate Communications 44
Oct 02, 2018: Michael Spiteri appointed non-executive director to help drive digitization strategy 44
Jul 02, 2018: Ergomed Names Stuart Jackson As Chief Financial Officer 45
Dec 15, 2017: Stephen Stamp appointed as CEO and Jan Petracek as COO 47
Dec 15, 2017: Ergomed Board appointed Stephen Stamp as CEO and Jan Petracek as COO 48
Apr 13, 2017: Ergomed Announces Board and Management Changes 49
Other Significant Developments 50
Jun 15, 2018: Ergomed Announces Registered Office Address Change 50
Mar 05, 2018: Ergomed: Trading Update and Notice of Preliminary Results 51
Jan 25, 2018: Ergomed 2017 Trading Update 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Ergomed Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ergomed Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ergomed Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Ergomed Plc, Medical Devices Deals, 2012 to YTD 2018 10
Ergomed Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Haemostatix Raises USD0.1 Million in Venture Financing 13
Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 15
Ergomed Enters into Co-Development Agreement with Asarina Pharma 16
Ergomed Enters into Co-Development Agreement with Dilaforette 17
Ergomed Clinical Research Enters Into Co-Development Agreement With Ferrer 18
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 19
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 20
Cel-Sci Expands Co-Development Agreement with Ergomed 21
Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 22
Ergomed Enters into Licensing Agreement with Boryung Pharma 23
Ergomed Raises USD5.5 Million in Private Placement of Shares 24
Ergomed Raises USD2.2 Million in Private Placement of Shares 25
Ergomed Announces Underwriter’s Exercise of Over-Allotment Option of Private Placement for USD10.4 Million 26
Ergomed Raises USD19 Million in IPO 27
Ergomed Acquires PSR Group for USD6.7 Million 28
Ergomed Acquires Dr.Oestreich +Partner and Gesellschaft fur angewandte Statistik + Datenanalyse 29
Ergomed Acquires Haemostatix 30
Ergomed Acquires Sound Opinion 32
Ergomed Plc, Key Competitors 33
Ergomed Plc, Key Employees 34
Ergomed Plc, Subsidiaries 35

List of Figures
Ergomed Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ergomed Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ergomed Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Ergomed Plc (ERGO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Particle Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Particle Sciences Inc (Particle Sciences), a subsidiary of The Lubrizol Corp is a contract research organization that offers complete formulation, analytic, bioanalytic and clinical trial material manufacturing solutions. The organization concentrates on BCS II/III/IV molecules, biologics an …
  • International Coffee & Tea, LLC:企業の戦略・SWOT・財務情報
    International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report Summary International Coffee & Tea, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Diagnostica Stago SAS:企業の戦略的SWOT分析
    Diagnostica Stago SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ormat Technologies Inc (ORA):企業の財務・戦略的SWOT分析
    Ormat Technologies Inc (ORA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Intertape Polymer Group Inc (ITP):企業の財務・戦略的SWOT分析
    Intertape Polymer Group Inc (ITP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • ABO-Group NV (ABO):企業の財務・戦略的SWOT分析
    Summary ABO-Group NV (ABO-Group), formerly Thenergo NV/SA, is a renewable energy service provider. It offers energy services, soil, environment, geotechnics and waste management services. The company’s services include consulting, training and monitoring services. Its soil services comprise groundwa …
  • China Banking Corporation:企業の戦略・SWOT・財務情報
    China Banking Corporation - Strategy, SWOT and Corporate Finance Report Summary China Banking Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Axela Inc-医療機器分野:企業M&A・提携分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • ImpediMed Ltd (IPD):企業の財務・戦略的SWOT分析
    ImpediMed Ltd (IPD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mobile Telesystems:企業の戦略・SWOT・財務分析
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Boston Scientific Corp (BSX):医療機器:M&Aディール及び事業提携情報
    Summary Boston Scientific Corp (Boston Scientific) is a medical device company that develops, manufactures and markets devices used in a range of interventional medical procedures. The company offers products in seven business groups, namely, Interventional Cardiology, Cardiac Rhythm Management (CRM …
  • SK Telecom Co., Ltd.:企業の戦略・SWOT・財務分析
    SK Telecom Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary SK Telecom Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Fanuc Corp (6954):企業の財務・戦略的SWOT分析
    Fanuc Corp (6954) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Europ Assistance Holding SA:企業の戦略的SWOT分析
    Europ Assistance Holding SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Sc Arcada Con Srl:企業の戦略的SWOT分析
    Sc Arcada Con Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Gammon Infrastructure Projects Ltd (GAMMNINFRA)-エネルギー分野:企業M&A・提携分析
    Summary Gammon Infrastructure Projects Limited (GIPL) is an infrastructure project development company. It undertakes projects on a public private partnership basis (PPP) across various sectors including hydro power, roads and expressways, ports, urban infrastructure, airports, special economic zone …
  • RPC Group PLC:企業の戦略・SWOT・財務分析
    RPC Group PLC - Strategy, SWOT and Corporate Finance Report Summary RPC Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ra Medical Systems Inc (RMED):企業の製品パイプライン分析
    Summary Ra Medical Systems Inc (Ra Medical Systems) is a medical device company that develops, designs, and commercializes excimer laser systems for the treatment of cardiovascular and dermatologic diseases. The company’s technology provides operational versatility and dose customization. Its produc …
  • Cisco Systems, Inc (CSCO)-石油・ガス分野:企業M&A・提携分析
    Summary Cisco Systems, Inc (Cisco) is a technology services provider, which designs, manufactures and sells Internet protocol (IP)-based networking systems and other products. The company’s products include blade switches, analytics and automation software, application networking services, interface …
  • Mayne Pharma Group Ltd (MYX)-製薬・医療分野:企業M&A・提携分析
    Summary Mayne Pharma Group Ltd (Mayne Pharma), formerly Mayne Pharma International Pty Ltd, a subsidiary of Hospira Inc, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise astrix capsules and tablets, erymax cap …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆